secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001104659-24-004548
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive RCT results for CytoSorb in heart transplant show reduced organ failure and shorter ICU stays
--------------------------------------------------------------------------------

- Vasoplegic syndrome rate 20% vs 48% control (p=0.028); odds 6.4× lower in CytoSorb group.
- Acute kidney injury 36.7% vs 76.0% control (p=0.004); no renal replacement therapy needed (0% vs 16%).
- Median ICU stay 8.5 days vs 12 days control (p=0.022); mechanical ventilation 25 vs 65 hours.
- No removal of anti-rejection drug mycophenolic acid and no device-related adverse events reported.
- Study published in European Society of Cardiology journal ESC Heart Failure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924004548/0001104659-24-004548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924004548/tm243541-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-004548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer